Abstract
A pharmaceutical formulation was designed which reduces the viral load of RSV in the nasal mucosa of rats after application immediately before inoculation and then daily for 4 days. The formulation did not cause irritation in the mucosal membranes or any other ill effects in intranasally treated rats. The formulation is composed of lauric acid and monocaprin as virucidal lipids, propylene glycol as a solvent, a polysorbate as a surfactant and Carbopol 974P, which has bioadhesive properties causing the formulation to adhere to mucosal membranes. Formulations without lipids were also found to exhibit antiviral activity in the nasal mucosa although apparently less than the formulation with lipids which caused a significant reduction in the viral load compared with controls receiving saline (P < 0.01). The formulation may have potential as a nasal spray to suppress or ameliorate respiratory infections by RSV and other enveloped viruses.
| Original language | English |
|---|---|
| Pages (from-to) | 455-457 |
| Number of pages | 3 |
| Journal | Journal of Drug Delivery Science and Technology |
| Volume | 23 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2013 |
Other keywords
- Antimicrobial
- Lauric acid
- Monocaprin
- Nasal mucosa
- Nasal spray
- Pharmaceutical formulations
- Respiratory infections
- Respiratory syncytial virus
- Virucidal lipids
Fingerprint
Dive into the research topics of 'Intranasal delivery of formulations containing virucidal lipids for treatment of respiratory syncytial virus (RSV) infection in rats'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver